Results 11 to 20 of about 55,457 (267)

nab-Paclitaxel for the treatment of pancreatic cancer.

Cancer management and research, 2017
Nanoparticle albumin-bound paclitaxel (nab-P) plus gemcitabine (Gem) became a standard treatment option for metastatic pancreatic cancer (MPC) following positive results from a global phase III trial (MPACT). A large number of studies have now published results on the use of nab-P/Gem to treat advanced and early-stage disease, warranting a ...
Kim G, George Kim, Kim, George
openaire   +5 more sources

Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study

Gynecologic Oncology Reports
The goal of this study was to assess the safety of nab-paclitaxel in patients with ovarian cancer or endometrial cancer who had an allergic reaction to paclitaxel.
Swapna Kochuveettil, Roberto Angeli Morales, Alicja Kaminska, Gerardo Colon-Otero   +3 more
doaj   +2 more sources

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use [PDF]

Farmacia Hospitalaria, 2015
Objective: To evaluate the results obtained with the combined use of nab-paclitaxel and gemcitabine in the treatment of patients with metastatic pancreatic adenocarcinoma. Materials and methods: Retrospective observational study.
Elena Ferris Villanueva, Mónica Martínez Penella, Pablo Cerezuela Fuentes, Rocío Guerrero Bautista, Andrés García Márquez, María Del Carmen Mira Sirvent   +5 more
doaj   +2 more sources

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

ClinicoEconomics and Outcomes Research, 2013
Carlo Lazzaro,1 Roberto Bordonaro,2 Francesco Cognetti,3 Alessandra Fabi,3 Sabino De Placido,4 Grazia Arpino,4 Paolo Marchetti,5 Andrea Botticelli,5 Paolo Pronzato,6 Elisa Martelli7 1Studio di Economia Sanitaria, Milan, Italy; 2Public Hospital Trust ...
Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E   +9 more
doaj   +3 more sources

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer

International Journal of Nanomedicine, 2015
Liang Huang,1,2 Sheng Chen,1,2 Ling Yao,1,2 Guangyu Liu,1,2 Jiong Wu,1,2 Zhiming Shao1–3 1Department of Breast Surgery, Fudan University Shanghai Cancer Center/Cancer Institute, 2Department of Oncology, Shanghai Medical College, 3Institutes of ...
Huang L, Chen S, Yao L, Liu GY, Wu J, Shao ZM   +5 more
doaj   +1 more source

Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks

Scientific Reports
Nab-paclitaxel (albumin-bound paclitaxel) and traditional paclitaxel are both used in pancreatic cancer treatment, but their adverse event (AE) profiles may differ due to formulation differences.
Nan Qin, Zhongliu Bian, Jingtao Chen
doaj   +2 more sources

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer Management and Research, 2017
Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C   +5 more
doaj   +1 more source

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer [PDF]

British Journal of Cancer, 2013
Nab-paclitaxel and gemcitabine have demonstrated a survival benefit over gemcitabine alone in advanced pancreatic cancer (PDA). This study aimed to investigate the clinical, biological, and imaging effects of the regimen in patients with operable PDA.Patients with operable PDA received two cycles of nab-paclitaxel and gemcitabine before surgical ...
Alvarez, R, Musteanu, M, Garcia-Garcia, E, Lopez-Casas, P P, Megias, D, Guerra, Carmen::1131::600, Tabernero, S, Mu�oz, M, Quijano, Y, Cubillo, A, Rodriguez-Pascual, J, Plaza, C, de Vicente, E, Prados, S, Barbacid, Mariano::2355::600, Lopez-Rios, F, Hidalgo, M   +16 more
openaire   +4 more sources

Albumin-bound paclitaxel in solid tumors: clinical development and future directions

Drug Design, Development and Therapy, 2015
Madappa N Kundranda,1 Jiaxin Niu21Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, 2Department of Medical Oncology, Cancer Treatment Centers of America, Goodyear, Arizona, USA Abstract: Albumin-bound paclitaxel (nab-paclitaxel) is a solvent ...
Kundranda MN, Niu J
doaj   +1 more source

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

Cancer Management and Research, 2018
Reshma L Mahtani,1 Monika Parisi,2 Stefan Glück,3 Quanhong Ni,2 Siyeon Park,4 Corey Pelletier,2 Claudio Faria,2 Fadi Braiteh5,6 1Division of Hematology/Oncology, University of Miami, Miami, FL, 2Health Economics and Outcomes Research, Celgene ...
Mahtani RL, Parisi M, Glück S, Ni Q, Park S, Pelletier C, Faria C, Braiteh F   +7 more
doaj   +1 more source